肢端肥大症：全球市場展望、流行病學、競爭格局與市場預測報告（32個主要市場），2025-2035年

市場概覽

• 預計到 2035 年，法國肢端肥大症市場規模將從約 4.2 億美元成長到 6.3 億美元。
• 以下因素正在推動市場成長：
• 擴大生長抑制素類似物和標靶治療的應用
• 改善慢性病的長期管理
• 市場規模的擴大是由於治療持續時間延長和高品質生物製藥的出現。
• 未來的成長取決於下一代內分泌療法和個人化治療策略。

鹿角珊瑚概述

肢端肥大症是一種緩慢進展、進行性生長，通常由良性腦下垂體腺瘤引起的生長激素 (GH) 慢性過度分泌，導致胰島素樣生長因子 1 (IGF-1) 水平升高。由於起病緩慢，診斷常常延遲 4 至 10 年。患者通常表現為肢體顯著增大，呈鏟形，臉部嚴重畸形，以及危及生命的全身性併發症，包括嚴重的心血管疾病和第 2 型糖尿病。主要標準治療方法是經蝶竇內視鏡手術切除腫瘤，以快速達到生化治癒。如果病灶持續存在，則必須使用生長抑制素受體配體 (SRL) 和生長激素受體標靶治療進行標靶治療，以使 IGF-1 水平正常化，抑制組織生長，並降低過早死亡的風險。

主要亮點

• 根據預測，德國肢端肥大症患者人數將從 2025 年的約 6,726 人增加到 2035 年的 7,022 人。
• 肢端肥大症是一種罕見的內分泌疾病，主要由分泌生長激素的腦下垂體腺瘤所引起。
• 由於症狀緩慢，診斷延誤仍然是一個重大挑戰。
• 長期併發症包括心血管疾病、代謝失調和生活品質下降。
• 醫療手段和疾病監測技術的進步提高了疾病控制率。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

• Alexion Pharmaceuticals, Inc.
• Crinetics Pharmaceuticals Inc.
• Camurus AB
• Debiopharm International SA
• Marea Therapeutics
• Immunwork, Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法－概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興治療方法。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Acromegaly Market Outlook

Thelansis's "Global Acromegaly Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acromegaly treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Acromegaly Overview

Acromegaly is an insidious, debilitating endocrine disorder characterized by progressive somatic overgrowth driven by chronic growth hormone (GH) hypersecretion-typically from a benign pituitary adenoma-and the subsequent elevation of insulin-like growth factor 1 (IGF-1). Because onset is subtle, diagnosis is notoriously delayed by 4 to 10 years. Patients classically develop distinctly enlarged, spade-like hands and feet, profound facial distortion, and life-threatening systemic morbidities, including severe cardiovascular disease and type 2 diabetes. The primary therapeutic standard is endoscopic transsphenoidal surgical resection to remove the tumor and achieve prompt biochemical cure. For persistent disease, targeted medical management-utilizing somatostatin receptor ligands (SRLs) and GH receptor antagonists-is definitively required to normalize IGF-1 levels, halt tissue proliferation, and mitigate the risk of premature mortality.

Key Highlights

• In Germany, prevalent acromegaly cases are projected to increase from approximately 6,726 in 2025 to 7,022 by 2035.
• Acromegaly is a rare endocrine disorder caused primarily by growth hormone-secreting pituitary adenomas.
• Delayed diagnosis remains a major challenge due to the gradual onset of symptoms.
• Long-term complications include cardiovascular disease, metabolic disorders, and reduced quality of life.
• Advances in medical therapies and disease monitoring are improving disease control rates.

Market Overview

• The France acromegaly market is projected to grow from approximately $420 MN to $630 MN by 2035.
• Market growth is supported by:
• Increasing utilization of somatostatin analogs and targeted therapies
• Improved long-term management of chronic disease
• Market value growth is driven by prolonged treatment duration and premium biologic therapies.
• Future growth will depend on next-generation endocrine therapies and personalized treatment strategies.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Crinetics Pharmaceuticals Inc.
• Camurus AB
• Debiopharm International SA
• Marea Therapeutics
• Immunwork, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)